NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
Status:
Not yet recruiting
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase III open-label, 3-arm, parallel, randomized, controlled trial. The allocation
ratio 1:1:1 and outcome assessment are blind to group allocation. Patients will be randomized
from 3 arms. Patients will receive VRD extended + ASCT plus ERI or Isatuximab-VRD + ASCT or
Isatuximab-VID + ASCT.
Phase:
Phase 3
Details
Lead Sponsor:
PETHEMA Foundation
Collaborators:
Adknoma Bristol-Myers Squibb Sanofi Start from scratch